<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03374007</url>
  </required_header>
  <id_info>
    <org_study_id>Gxplore-001</org_study_id>
    <nct_id>NCT03374007</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma</brief_title>
  <acronym>GB226</acronym>
  <official_title>With Open, Single/Multiple Dosing and Dose Escalation, Phase I Clinical Trial Scheme to Evaluate Safety, Tolerance and Pharmacokinetic Properties of Genolimzumab Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genor Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genor Biopharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With open, single/ multiple dosing and dose escalation, phase I clinical trial scheme to&#xD;
      evaluate safety, tolerance and pharmacokinetic properties of Genolimzumab injection in&#xD;
      Chinese patients of advanced and (or) recurrent solid tumor/lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recombinant Programmed death-1(PD-1) humanized monoclonal antibody injection (company code:&#xD;
      GB226) is joint developed by Genor Biopharma Co. Ltd and Crown Bioscience,Inc., it is the&#xD;
      reorganization of deoxyribonucleic acid (DNA) technology in the Chinese hamster ovary (CHO)&#xD;
      cells express system expressed in a immunoglobulin G4 (IgG4) kappa type single resistance to&#xD;
      predominate. GB226 had the different new amino acid sequence and molecular structure compared&#xD;
      with two marketed PD-1 monoclonal antibody injection and got the approval of China Food and&#xD;
      Drug Administration (CFDA) for clinical trial.Pharmaceutical research indicated GB226 cell&#xD;
      strain had security source, production process is stable, quality can control, preparation&#xD;
      stability, has good compatibility with packaging materials, it has the condition of&#xD;
      industrialization, can prepare investigational medicinal product with safety, effective, and&#xD;
      controlled quality for clinical research.Pharmacodynamics study show the targets and&#xD;
      mechanisms of GB226 is clear, tumor suppression effect is obvious.Toxicology studies show&#xD;
      this product in high doses with low toxic, and the toxic is reversible, the most common&#xD;
      toxicity is specific to the drug action mechanism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse event</measure>
    <time_frame>all adverse events will be recorded from the time the consent form is signed through 30 days following cessation of treatment.</time_frame>
    <description>adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Event</measure>
    <time_frame>all serious adverse events will be recorded from the time the consent form is signed through 30 days following cessation of treatment.</time_frame>
    <description>Serious Adverse Event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting Toxicity, DLT</measure>
    <time_frame>Day 1 to Day 28 after first dose</time_frame>
    <description>Dose limiting Toxicity, DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose, MTD</measure>
    <time_frame>Day 1 to Day 28 after first dose</time_frame>
    <description>Maximum Tolerated Dose, MTD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC 0-t</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>AUC 0-t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C max</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>C max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-∞</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>AUC 0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T max</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>T max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Vd</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ke</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Ke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t 1/2</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>t 1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>CL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody, ADA</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Anti-drug antibody, ADA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IFN-γ concentration</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>IFN-γ concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peripheral blood CD8+PD-1 receptor occupying ratio</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>peripheral blood CD8+PD-1 receptor occupying ratio</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Recurrent Solid Tumor</condition>
  <condition>Lymphoma</condition>
  <condition>Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>GB226 1mg/kg single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geptanolimab, 1mg/kg, i.v., single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB226 3 mg/kg single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geptanolimab, 3mg/kg, i.v., single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB226 10mg/kg single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geptanolimab 10mg/kg, i.v., single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB226 1mg/kg multiple dosing, every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geptanolimab, 1mg/kg, i.v., q2w*6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB226 3mg/kg multiple dosing,every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geptanolimab, 3mg/kg, i.v., q2w*6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB226 10mg/kg multiple dosing, every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geptanolimab,10mg/kg, i.v., q2w*6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB226 280mg multiple dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geptanolimab, 280mg, i.v., q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB226 3mg/kg multiple dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geptanolimab, 3mg/kg, i.v., q2w</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Geptanolimab Injection 1mg/kg</intervention_name>
    <description>single-dose:1mg/kg</description>
    <arm_group_label>GB226 1mg/kg single-dose</arm_group_label>
    <other_name>Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Geptanolimab Injection 3mg/kg</intervention_name>
    <description>single-dose: 3mg/kg</description>
    <arm_group_label>GB226 3 mg/kg single-dose</arm_group_label>
    <other_name>Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Geptanolimab Injection 10mg/kg</intervention_name>
    <description>single-dose:10mg/kg</description>
    <arm_group_label>GB226 10mg/kg single-dose</arm_group_label>
    <other_name>Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Geptanolimab Injection 1mg/kg, q2w*6</intervention_name>
    <description>multiple dosing: 1mg/kg, q2w*6</description>
    <arm_group_label>GB226 1mg/kg multiple dosing, every 2 weeks</arm_group_label>
    <other_name>Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Geptanolimab Injection 3mg/kg, q2w*6</intervention_name>
    <description>multiple dosing: 3mg/kg, q2w*6</description>
    <arm_group_label>GB226 3mg/kg multiple dosing,every 2 weeks</arm_group_label>
    <other_name>Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Geptanolimab Injection 10mg/kg, , q2w*6</intervention_name>
    <description>multiple dosing: 10mg/kg, , q2w*6</description>
    <arm_group_label>GB226 10mg/kg multiple dosing, every 2 weeks</arm_group_label>
    <other_name>Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Geptanolimab Injection 280mg, q3w</intervention_name>
    <description>multiple dosing: 280mg, q3w</description>
    <arm_group_label>GB226 280mg multiple dosing</arm_group_label>
    <other_name>Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Geptanolimab Injection 3mg/kg, q2w</intervention_name>
    <description>multiple dosing: 3mg/kg, q2w</description>
    <arm_group_label>GB226 3mg/kg multiple dosing</arm_group_label>
    <other_name>Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age: 18-65. Unisex.&#xD;
&#xD;
          -  2. Understand trial procedure and content and sign informed consent voluntarily;&#xD;
&#xD;
          -  3. Patients of advanced (phase Ⅲb, multidisciplinary treatment is not appropriate),&#xD;
             metastatic (phase IV) or recurrent solid tumor (including melanoma, NSCLC, renal cell&#xD;
             carcinoma, head &amp; neck cancer, esophagus cancer, liver cancer, bladder cancer,&#xD;
             spongioblastoma) or lymphoma (classical hodgkin lymphoma and (or) peripheral T-cell&#xD;
             lymphoma, natural killer (NK)-T cell lymphoma and mediastinal B cell lymphoma)&#xD;
             conformed by histology or cytology and cannot be cured by surgery. There is no&#xD;
             effective standard treatment now.&#xD;
&#xD;
          -  4. Agree to provide recorded tumor tissue sample or fresh tissue sample.&#xD;
&#xD;
          -  5. Eastern Cooperative Oncology Group (ECOG): 0-1;&#xD;
&#xD;
          -  6. Expected life ≥ 3 months;&#xD;
&#xD;
          -  7. With at least one measurable and evaluable tumor (solid tumor is subject to&#xD;
             criteria for evaluating efficacy of Immune-Related Response Criteria (irRC)/RECIST and&#xD;
             lymphoma is subject to criteria/revised criteria of international working group);&#xD;
&#xD;
          -  8. Chemotherapy of the whole body is completed at least 4 weeks before inclusion.&#xD;
&#xD;
          -  9. Radiotherapy of the whole body and partial palliative radiotherapy are completed at&#xD;
             least 4 weeks before inclusion.&#xD;
&#xD;
          -  10. Corticosteroids (prednisone&gt;10mg/d or equivalent) has been stopped at least 2&#xD;
             weeks before inclusion.&#xD;
&#xD;
          -  11. Autotransplantation is completed at least 3 months before inclusion.&#xD;
&#xD;
          -  12. Major surgeries with the need of general anesthesia are completed at least 4&#xD;
             weeks. Surgeries with the need of local anesthesia/epidural anesthesia are completed&#xD;
             at least 2 weeks and the subjects have recovered. Skin biopsies with the need of local&#xD;
             anesthesia are completed at least 1 hour before inclusion.&#xD;
&#xD;
          -  13. Previous tumor biotherapy (tumor vaccine, cell factor or growth factor for the&#xD;
             purpose of tumor control) is completed at least 4 weeks before inclusion;&#xD;
&#xD;
          -  14. Without severe haematological, cardiopulmonary, liver and kidney diseases except&#xD;
             protopathic. For patients of solid tumor, hemoglobin≥9g/dl, neutrophile&#xD;
             granulocyte≥1.5×109/L, blood platelet≥100×1012/L. For patients of hematologic tumor,&#xD;
             hemoglobin≥8g/dl, neutrophile granulocyte≥1.0×109/L, blood platelet≥80×1012/L.&#xD;
&#xD;
          -  15. Serum creatinine≤1.5xUpper Limit Of Normal (ULN) or creatinine clearance&#xD;
             rate≥50mL/min and urine protein&lt;2+ in test paper of urine. For patients with urine&#xD;
             protein great than or equal to 2+ in test paper of urine, urine shall be collected in&#xD;
             24 hours and urine protein must less than or be equal to 1g.&#xD;
&#xD;
        etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Active central nervous system metastasis; If central nervous system (CNS)&#xD;
             metastasis of patients can be treated and their symptoms of nervous system can recover&#xD;
             to the baseline level (excluding residual signs or symptoms related to CNS treatment)&#xD;
             for 2 weeks when they are included, they can participate in the research. Cranial CT&#xD;
             or MRI scanning shall be made for the patients 30 days before inclusion.&#xD;
&#xD;
          -  2. Meningeal metastases or meningeal infiltration of tumors;&#xD;
&#xD;
          -  3. Patients with other malignant tumors (excluding cured cervical carcinoma in situ&#xD;
             and skin basal cell carcinoma) shall not participate in the research, unless he/she&#xD;
             has been fully relieved at least 2 years without the need of other treatment or other&#xD;
             treatment is not needed during the research.&#xD;
&#xD;
          -  4. With active, known or suspected autoimmune disease.&#xD;
&#xD;
          -  5. With previous usage of PD-1 antibody, PD-L1 antibody, PD-L2 antibody or cytotoxic&#xD;
             T-lymphocyte-associated antigen-4 immunoglobulin (CTLA-4) antibody for treatment (or&#xD;
             other antibody for co-stimulation or check point assess of T cells)&#xD;
&#xD;
          -  6.With severe internal medicine diseases, including severe heart disease,&#xD;
             cerebrovascular disease, uncontrolled diabetes, uncontrolled high blood pressure,&#xD;
             active peptic ulcer, active bleeding.&#xD;
&#xD;
          -  7. With active infection.&#xD;
&#xD;
          -  8. With active tuberculosis infection; with active tuberculosis infection in the past.&#xD;
&#xD;
          -  9. Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab),&#xD;
             acquired immunodeficiency syndrome antibody (Anti-HIV) and treponema pallidum antibody&#xD;
             (TP-Ab). Positive subjects of HBsAg may not be excluded from patients of liver cancer.&#xD;
&#xD;
          -  10. Complication with the need of immunosuppressive drug or complication with the need&#xD;
             of corticosteroids for whole or partial body in the dosage of immunosuppressive&#xD;
             action.&#xD;
&#xD;
        etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawn Yu, Master</last_name>
    <phone>86-010-65260820</phone>
    <email>shawn.yu@genorbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuankai Shi, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Yuankai Shi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Qingyuan Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 6, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make individual participant data available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

